A
A. Douglas Laird
Researcher at Pfizer
Publications - 35
Citations - 5383
A. Douglas Laird is an academic researcher from Pfizer. The author has contributed to research in topics: Receptor tyrosine kinase & Platelet-derived growth factor receptor. The author has an hindex of 17, co-authored 30 publications receiving 4821 citations.
Papers
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal ArticleDOI
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes,Jason Chen,Jenny Tan,Kyoko Yamaguchi,Yongchang Shi,Peiwen Yu,Fawn Qian,Felix Chu,Frauke Bentzien,Belinda Cancilla,Jessica Orf,Andrew You,A. Douglas Laird,Stefan Engst,Lillian Lee,Justin Lesch,Yu-Chien Chou,Alison Joly +17 more
TL;DR: Treatment with cabozantinib is suggested to be a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
Journal Article
SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors
A. Douglas Laird,Peter Vajkoczy,Laura K. Shawver,Andreas Thurnher,Congxin Liang,Moosa Mohammadi,Joseph Schlessinger,Axel Ullrich,Stevan R. Hubbard,Robert A. Blake,T. Annie T. Fong,Laurie M. Strawn,Li Sun,Cho Tang,Rachael E. Hawtin,Flora Tang,Narmada Shenoy,K. Peter Hirth,Gerald McMahon,Julie M. Cherrington +19 more
TL;DR: Oral or i.p. administration of SU6668 in athymic mice resulted in significant growth inhibition of a diverse panel of human tumor xenografts of glioma, melanoma, lung, colon, ovarian, and epidermoid origin, and intravital multifluorescence videomicroscopy of C6glioma xenografteds in the dorsal skinfold chamber model revealed thatSU6668 treatment suppressed tumor angiogenesis.
Journal ArticleDOI
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes,Florian H. Heidel,Andrzej Hellmann,Walter Fiedler,B. Douglas Smith,Tadeusz Robak,Pau Montesinos,Daniel A. Pollyea,Pierre Desjardins,Oliver G. Ottmann,Weidong Wendy Ma,Naveed Shaik,A. Douglas Laird,Mirjana Zeremski,Ashleigh O'Connell,Geoffrey Chan,Michael Heuser +16 more
TL;DR: Glasdegib plus LDAC has a favorable benefit–risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy and clinical efficacy was evident across patients with diverse mutational profiles.
Journal ArticleDOI
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
TL;DR: It has become clear that unleashing the full therapeutic potential of tyrosine kinase inhibitors will require patient preselection, better assays to guide dose selection, knowledge of mechanism-based side effects and ways to predict and overcome drug resistance.